Lipid-based nanoparticles
Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-β plaque deposits characteristic of Alzheimer's Disease.
1. A liposomal composition, comprising:
a membrane, comprising:
a first phospholipid;
cholesterol;
a second phospholipid, the second phospholipid being derivatized with a polymer; a third phospholipid, the third phospholipid being a phospholipid-polymer-aromatic compound conjugate,
the phospholipid-polymer-aromatic compound conjugate being represented by:
wherein n is about 10 to about 100; and
a nonradioactive magnetic resonance imaging (MM) contrast enhancing agent at least one of encapsulated by or bound to the membrane.
2. The liposomal composition of claim 1 ,
wherein n is about 30 to about 60.
3. The liposomal composition of claim 1 , wherein:
the phospholipid-polymer-aromatic compound conjugate is represented by:
wherein n is about 10 to about 100.
4. The liposomal composition of claim 3 , wherein n is about 30 to about 60.
5. The liposomal composition of claim 1 , wherein the nonradioactive MRI contrast enhancing agent comprises gadolinium.
6. A method for imaging amyloid deposits in a patient, the method comprising:
introducing into the patient a detectable quantity of a liposomal composition comprising:
a membrane, comprising:
a first phospholipid;
cholesterol;
a second phospholipid, the second phospholipid derivatized with a polymer; and
a third phospholipid, the third phospholipid being a phospholipid-polymer-aromatic compound conjugate represented by:
wherein n is about 10 to about 100; and
a nonradioactive magnetic resonance imaging (MRI) contrast enhancing agent at least one of encapsulated by or bound to the membrane;
allowing sufficient time for the liposomal composition to be associated with one or more amyloid deposits; and
detecting the liposomal composition associated with the one or more amyloid deposits.
7. The method of claim 6 , wherein the nonradioactive MRI contrast enhancing agent comprises gadolinium.
8. The method of claim 6 , wherein the detecting comprises detecting using magnetic resonance imaging.
9. The method of claim 6 ,
wherein n is about 30 to about 60.
10. The method of claim 6 , wherein the phospholipid-polymer-aromatic compound conjugate is represented by:
wherein n is about 10 to about 100.
11. A liposomal composition for capturing images of amyloid deposits on a patient's brain, the liposomal composition comprising:
DPPC;
cholesterol;
DSPE-mPEG-2000; and
wherein: n is about 10 to about 100; and
Gd-DTPA-BSA.
12. The liposomal composition of claim 11 , wherein n is about 30 to about 60.